- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06362473
Lipid Transport Disorder Italian Genetic Record (LIPIGEN) (LIPIGEN)
LIPIGEN is an observational study involving Italian physicians and researchers in the field of diseases related to blood lipid levels. This study aims to improve the diagnosis and treatment of people with familial dyslipidaemias, including very common conditions such as familial hypercholesterolaemia (FH) and less common ones such as familial chylomicronidaemic syndrome (FCS).
What does the study do?
It collects information on Italian patients with Familial Hypercholesterolaemia (FH), following them in their normal clinical examination without adding extra procedures.
It uses the data collected to further our understanding of diseases such as familial hypercholesterolaemia, examining how it is diagnosed clinically and by genetic testing, and evaluating the effectiveness of different treatments.
It seeks to identify the genetic mutations that cause familial hypercholesterolaemia and other dyslipidaemias, helping to choose the most effective treatments.
It evaluates the impact of long-term treatments and patient adherence to medication, as well as monitoring the incidence of cardiovascular events and other important outcomes.
Who can participate?
The study is aimed at people of all ages, from children to adults, with familial hypercholesterolaemia or other genetic dyslipidaemia.
More than 50 centres throughout Italy are involved, making the study accessible to many.
What does participation entail?
Participants will continue with their normal clinical practice.
Data such as family history, personal clinical findings and genetic information will be collected, without additional procedures.
For some, further evaluations, such as ultrasounds, may be required to better study their condition.
The LIPIGEN study not only helps to better understand diseases related to high cholesterol but also aims to improve patients' lives through more precise diagnosis and personalised treatments.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Manuela Casula, PhD
- Phone Number: 0039 + 0250318428
- Email: manuela.casula@unimi.it
Study Locations
-
-
Milano
-
Sesto san Giovanni, Milano, Italy, 20099
- Recruiting
- IRCCS MultiMedica
-
Contact:
- Fabio Pellegatta, MD
- Phone Number: 00390224209593
- Email: lipigen@sisa.it
-
Principal Investigator:
- Fabio Pellegatta, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Molecular or clinical diagnosis of genetic dyslipidemia
- Informed consent signed
Exclusion Criteria:
- None
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Lipid profile of patients with genetic dyslipidemia
Time Frame: At baseline evaluation
|
Lipid profile of patients with molecular or clinical diagnosis of genetic dyslipidemia:
|
At baseline evaluation
|
Genetic profile of patients with genetic dyslipidemia
Time Frame: At baseline evaluation
|
Genetic profile of patients with molecular or clinical diagnosis of genetic dyslipidemia:
|
At baseline evaluation
|
Collaborators and Investigators
Investigators
- Study Chair: Alberico L Catapano, PhD, Fondazione S.I.S.A.
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LIPIGEN-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Familial Hypercholesterolemia
-
National Medical Research Center for Therapy and...Moscow State University of Medicine and DentistryRecruitingMedication Adherence | Adherence, Medication | Treatment Adherence | Familial Hypercholesterolemia | Motivational Interviewing | Adherence, Patient | Treatment Adherence and Compliance | Patient Compliance | Adherence | Hypercholesterolemia, Familial | Patient Adherence | Hypercholesterolemia, Autosomal Dominant and other conditionsRussian Federation
-
Regeneron PharmaceuticalsSanofiTerminatedHeterozygous Familial Hypercholesterolemia | Non-familial HypercholesterolemiaUnited States, Bulgaria, Estonia, Russian Federation, South Africa, Ukraine
-
Merck Sharp & Dohme LLCTerminatedHypercholesterolemia, Familial | Heterozygous Familial Hypercholesterolemia
-
Institut Investigacio Sanitaria Pere VirgiliRecruitingFamilial Hypercholesterolemia | Familial Hypercholesterolemia - Homozygous | Familial Hypercholesterolemia - HeterozygousSpain
-
Novartis PharmaceuticalsActive, not recruitingFamilial Hypercholesterolemia - HomozygousGreece, Lebanon, Turkey, France, Canada, Malaysia, Netherlands, United States
-
Novartis PharmaceuticalsRecruitingHeterozygous or Homozygous Familial HypercholesterolemiaNetherlands, Israel, Hungary, Italy, Germany, Spain, France, Norway, South Africa, Turkey, United Kingdom, Canada, Switzerland, Brazil, Lebanon, Slovenia, United States, Russian Federation, Taiwan
-
Novartis PharmaceuticalsCompletedElevated Cholesterol | Homozygous Familial Hypercholesterolemia | Heterozygous Familial Hypercholesterolemia | ASCVDUnited States, Canada, Czechia, Denmark, Germany, Hungary, Netherlands, Poland, South Africa, Spain, Sweden, Ukraine, United Kingdom
-
REGENXBIO Inc.National Heart, Lung, and Blood Institute (NHLBI)TerminatedHomozygous Familial Hypercholesterolemia (HoFH)United States, Canada, Italy, Netherlands
-
University of British ColumbiaVancouver Coastal Health Research Institute; Genome British ColumbiaRecruitingAcute Coronary Syndrome | Familial Hypercholesterolemia | STEMI | NSTEMI - Non-ST Segment Elevation MI | Familial Hypercholesterolemia - Heterozygous | Familial Hypercholesterolemia Due to Genetic Defect of Apolipoprotein B | Familial Hypercholesterolemia Due to Heterozygous LDL Receptor Mutation and other conditionsCanada
-
Organon and CoCompletedPrimary Hypercholesterolemia | Homozygous Familial Hypercholesterolemia
Clinical Trials on Lipid-lowering treatments
-
Aarhus University HospitalHeartFlow, Inc.Completed
-
Samsung Medical CenterUnknownAcute Coronary SyndromeKorea, Republic of
-
Peter GædeActive, not recruiting
-
TakedaTerminatedHypercholesterolemiaFrance, United Kingdom, United States, Israel, Poland, Canada
-
Kumamoto UniversityCompletedMyocardial InfarctionJapan
-
Acasti Pharma Inc.JSS Medical Research Inc.CompletedHypertriglyceridemiaCanada
-
Novartis PharmaceuticalsCompletedAtherosclerotic Cardiovascular Disease | Atherosclerotic Cardiovascular Disease Risk Equivelents | Elevated Low Density Lipoprotein CholesterolUnited Kingdom
-
Endocrine Research SocietyCompleted
-
Organon and CoBayerCompletedHypercholesterolemia | Familial Hypercholesterolemia | Homozygous Sitosterolemia
-
Chinese Academy of Medical Sciences, Fuwai HospitalRecruitingCoronary Artery Disease ProgressionChina